文献速递瓣膜外科

微创开胸与胸骨正中切开在再次二尖瓣手术后的远期生存比较

Late Survival After Redo Mitral Operation With Minithoracotomy Compared With Sternotomy.
PubMed 文献 · Ann Thorac Surg · 2023-11-04

本研究基于1997至2022年前瞻性机构数据库,回顾接受再次二尖瓣手术且有既往胸骨切开史成人,比较再次胸骨正中切开与微创开胸的短期和远期结局。倾向性评分匹配后,微创开胸组10年生存率显著高于胸骨切开组(60%±5% vs 42%±5%,P=.0006),术后前6个月生存差异最大(96%±1% vs 81%±3%,P<.001)。

要点

  • 倾向匹配后微创开胸组10年生存率显著高于胸骨切开组(60%±5% vs 42%±5%,P=.0006)。
  • 术后前6个月生存差异最大(96%±1% vs 81%±3%,P<.001)。
  • 微创右前开胸可能显著降低再次二尖瓣手术后前6个月死亡风险,并持续至10年。

核心结论

  • 对于接受再次二尖瓣手术的患者,微创右前开胸可显著降低术后前6个月死亡风险,并持续带来至10年的生存获益。
  • 作者呈现大型单中心系列,提示通过更广泛使用右微创开胸,有机会持久改善再次二尖瓣手术后的结局。

研究设计与样本

  • 回顾性分析前瞻性维护的机构数据库,纳入1997年至2022年有既往胸骨切开史、接受再次胸骨正中切开或微创开胸二尖瓣手术的成人患者。
  • 共750例连续患者,其中微创开胸503例(67%);采用倾向性评分匹配比较短期和长期结局。
  • 中位随访5.0年(四分位距0-23年)。

主要发现

  • 胸骨切开组更常使用中央主动脉插管(205/223[93%] vs 265/481[56%])、心脏停搏液停跳(220/223[99%] vs 124/481[26%])和二尖瓣置换(190/223[85%] vs 358/481[74%])。
  • 微创开胸组年龄更大(63±13 vs 58±14岁),择期就诊比例更高(387/503[77%] vs 128/247[52%])。
  • 胸骨切开组感染性心内膜炎比例更高(52/247[21%] vs 45/503[9%],P<.001)。
  • 10年时微创开胸组生存改善(52%±3% vs 46%±4%,P=.004);倾向匹配后微创开胸组10年生存率显著更高(60%±5% vs 42%±5%,P=.0006)。
  • 术后前6个月生存差异最大(96%±1% vs 81%±3%,P<.001)。

临床怎么用

  • 作者认为,微创右前开胸可显著降低再次二尖瓣手术后前6个月死亡风险,并持续至10年生存获益。
  • 作者建议通过更广泛使用右微创开胸来持久改善再次二尖瓣手术后的结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term effectiveness of minithoracotomy over redo median sternotomy for reoperative mitral operation is not well described. Here we present long-term survival after reoperative mitral operation based on operative approach. METHODS: Adults undergoing mitral valve operation with previous sternotomy by redo sternotomy and minithoracotomy were reviewed from our prospectively maintained institutional database from 1997 to 2022. Propensity score matching was performed to compare short- and long-term outcomes. RESULTS: Of 750 consecutive patients, thoracotomy was performed in 503 (67%). Median follow-up was 5.0 years (interquartile range, 0-23 years). Intraoperatively, sternotomy patients were more likely to have central aortic cannulation (205 of 223 [93%] vs 265 of 481 [56%]), cardioplegic arrest (220 of 223 [99%] vs 124 of 481 [26%]), and mitral valve replacement (190 of 223 [85%] vs 358 of 481 [74%]). Thoracotomy patients were older (63 ± 13 vs 58 ± 14 years) with elective presentation (387 of 503 [77%] vs 128 of 247 [52%]). Sternotomy patients were more likely to have endocarditis (52 of 247 [21%] vs 45 of 503 [9%], P < .001). At 10 years, thoracotomy patients experienced improved survival (52% ± 3% vs 46% ± 4%, P = .004). After propensity matching, 10-year survival was significantly higher for thoracotomy patients compared with sternotomy patients (60% ± 5% vs 42% ± 5%, P = .0006). The greatest difference in survival was at the first 6 months after operation (96% ± 1% vs 81% ± 3%, P < .001). CONCLUSIONS: For patients undergoing reoperative mitral valve operation, minimally invasive right anterior thoracotomy can significantly decrease risk of death in the first 6 months, with durable survival benefit out to 10 years. We present a large single-center series to suggest an important opportunity to durably improve outcomes after reoperative mitral operation through wider use of right minithoracotomy.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Zwischenberger BA, Gaca JG, Milano C, et al. Late Survival After Redo Mitral Operation With Minithoracotomy Compared With Sternotomy. Ann Thorac Surg. 2023. PMID: 37930297. doi:10.1016/j.athoracsur.2023.08.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。